Mithat Gönen, PhD

Chief, Biostatistics Service

Pictured: Mithat Gönen


Texas Tech University

Current Research Interest 

Dr. Gönen has been at MSK since 1999 and has been serving as Chief of the Biostatistics Service since 2015. His translational and clinical collaborations focus on genomic profiling of hematologic malignancies, surgical treatment of gastrointestinal and hepatobiliary cancers and development and evaluation of novel molecular imaging technologies. Most of Dr. Gönen’s methodological research originates from these collaborations, including building, assessing and comparing prognostic and predictive models, design and analysis of clinical trials and imaging studies, as well as Bayesian methods. He is a recent awardee of the Foundation for NIH to study alternative response metrics in cancer clinical trials and the author of a book on the use of receiver operating characteristic curves using SAS®. Dr. Gönen served a co-director of the AACR/ASCO Vail Workshop on Methods in Clinical Cancer Research from 2011 to 2013 and was a member of ASCO’s Cancer Research Committee from 2012 to 2014. He has been serving the Society for Clinical Trials (SCT) in various roles: Program Chair for the 2012 Annual Meeting, deputy editor of Clinical Trials: Journal of the Society for Clinical Trials, member of the board of directors, member of the executive committee, and, most recently as President-Elect. Dr. Gönen is a fellow of the American Statistical Association (ASA), a fellow of the SCT, an associate editor of Statistics in Biopharmaceutical Research, an ASA journal, and a member of the board of reviewing editors for Science in Translational Medicine. He served the International Biometric Society as the Program Chair for its North America meeting in 2015.


Selected peer-reviewed publications:

  1. Weiser, M., Hsu, M., Bauer, P., Chapman, W., González, I., Chatterjee, D., Lingam, D., Mutch, M., Keshinro, A., Shia, J., Vakiani, E., Konishi, T., Shimada, Y., Stadler, Z., Segal, N., Cercek, A., Saltz, L., Yaeger, R., Varghese, A., Widmar, M., Wei, I., Pappou, E., Smith, J., Nash, G., Paty, P., Garcia-Aguilar, J., Gönen, M. Clinical Calculator Based on Molecular , Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer (2021) Journal of Clinical Oncology
  2. Devlin, S.M., Gönen, M., Heller, G. Measuring the temporal prognostic utility of a baseline risk score (2020) Lifetime Data Analysis, 26 (4), pp. 856-871.
  3. Capanu, M., Giurcanu, M., Begg, C.B., Gönen, M. Optimized variable selection via repeated data splitting (2020) Statistics in Medicine, 39 (16), pp. 2167-2184.
  4. Stetson, P.D., Cantor, M.N., Gonen, M. When predictive models collide (2020) JCO Clinical Cancer Informatics, (4), pp. 547-550.
  5. Li, Y., Schofield, E., Gönen, M. 36491947400;16317395300;7003560941; A tutorial on Dirichlet process mixture modeling (2019) Journal of Mathematical Psychology, 91, pp. 128-144.  

Visit PubMed for a full listing of Mithat Gönen’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Mithat Gönen discloses the following relationships and financial interests:

  • GLG Pharmaceuticals
    Provision of Services
  • Guidepoint Global Advisors
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures